Fri 21'st Apr 2017
RXI Pharmaceuticals Corporation Stock Analysis
Technical stock analysis for Fri 21'st Apr 2017
Sell candidate since 2017-04-20 Loss -3.35%
RXI Pharmaceuticals Corporation lies in the lower part of a very wide and strong rising trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at USD 0.64 will firstly indicate a slower raising rate, but may also be a early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 11.3% during the next 3 months and, with 90% probability hold a price between USD 0.71 and USD 0.99 at the end of this period.
There are few to none technical positive signals at the moment. RXI Pharmaceuticals Corporation holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at USD 0.69 and USD 0.76. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Wednesday April 19, 2017, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Relative Strength Index (RSI)
RSI14 is 31 and the stock is currently not being overbought or oversold
Support & Resistance
RXI Pharmaceuticals Corporation finds support from accumulated volume at USD 0.66, USD 0.63, and USD 0.63. On the upside the stock meets some resistance from accumulated volume at USD 0.76, USD 0.77 and USD 0.81.
This stock may move much during a day (volatility) and with periodic low trading volume this stockstock is considered to be "high risk". During the last day, the stock moved USD 0.04 between high and low, or 6.15%. For the last week the stock has had a daily average volatility of 12.96%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
The stock stock holds several negative signals and despite the positive trend we believe RXI Pharmaceuticals Corporation will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Hold/Accumulate to a Sell Candidate.